Cost-Utility Analysis of Drug Treatments in Patients with Polypoidal Choroidal Vasculopathy in Thailand

Overview

Journal Clinicoecon Outcomes Res

Publisher Dove Medical Press

Specialty Health Services

Date 2021 Nov 19

PMID 34795492

Authors

Sermsiri Sangroongruangsri

Usa Chaikledkaew

Prut Hanusaha

Tanapat Ratanapakorn

Paisan Ruamviboonsuk

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to estimate the cost-utility and budget impact of pharmacological treatments for the eye with polypoidal choroidal vasculopathy (PCV) in Thailand.

Methods: A Markov model-based cost-utility analysis (CUA) and budget impact analysis were conducted. The lifetime cost and outcomes of PCV treatments were estimated. We discounted costs and outcomes at 3% per annum. Parameters were estimated using data from published literatures, local cost and utility data, and epidemiology data among Thai patients. Univariate and probabilistic sensitivity analyses were performed to account for parameter uncertainty.

Results: Intravitreal bevacizumab (IVB) resulted in the lowest lifetime cost, followed by IVB plus verteporfin photodynamic therapy (IVB+vPDT) and intravitreal aflibercept (IVA). The combination of IVB or intravitreal ranibizumab (IVR) and verteporfin photodynamic therapy (IVB+vPDT or IVR+vPDT) yielded the highest quality-adjusted life-years (QALY). When compared with IVB from a societal perspective, the incremental cost-effectiveness ratio for patients with PCV receiving IVB+vPDT, IVR+vPDT, IVA were 10,304; 54,135; and 82,738 the United States dollar (USD) per QALY gained, respectively. At the Thai societal willingness to pay threshold of 4884 USD, IVB had the highest probability of being cost-effective (99%) followed by IVB+vPDT (1%). IVB+vPDT could be a cost-effective strategy and required a budget of 12.61 million USD over five fiscal years when the price of verteporfin reduced by approximately 45%.

Conclusion: None of the drug treatments for PCV was cost-effective in the Thai context. The decreased price of verteporfin is required to support the inclusion of IVB+vPDT in the Thai National List of Essential Medicines for the treatment of PCV.

References

Qian T, Li X, Zhao M, Xu X . Polypoidal choroidal vasculopathy treatment options: A meta-analysis. Eur J Clin Invest. 2017; 48(1). PMC: 5771464. DOI: 10.1111/eci.12840. View

Han L, Yuan L, Liang X, Jia X, Zhang M . Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis. Int J Ophthalmol. 2017; 10(8):1280-1289. PMC: 5554849. DOI: 10.18240/ijo.2017.08.16. View

Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T . Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003; 121(10):1392-6. DOI: 10.1001/archopht.121.10.1392. View

Wong C, Wong T, Cheung C . Polypoidal Choroidal Vasculopathy in Asians. J Clin Med. 2015; 4(5):782-821. PMC: 4470199. DOI: 10.3390/jcm4050782. View

Feng P, Lin J, Sakurada Y, Yannuzzi N, Smiddy W, Chilakamarri P . Cost and Outcomes Analysis of Polypoidal Choroidal Vasculopathy (Aneurysmal Type 1 Neovascularization) Treatment Strategies. J Vitreoretin Dis. 2023; 5(3):227-231. PMC: 9979034. DOI: 10.1177/2474126420946599. View

Brown M, Brown G, Sharma S, Busbee B . Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. Ophthalmology. 2003; 110(6):1076-81. DOI: 10.1016/S0161-6420(03)00254-9. View

Lim T, Lai T, Takahashi K, Wong T, Chen L, Ruamviboonsuk P . Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial. JAMA Ophthalmol. 2020; 138(9):935-942. PMC: 7366282. DOI: 10.1001/jamaophthalmol.2020.2443. View

Lim L, Mitchell P, Seddon J, Holz F, Wong T . Age-related macular degeneration. Lancet. 2012; 379(9827):1728-38. DOI: 10.1016/S0140-6736(12)60282-7. View

Wong C, Cheung C, Mathur R, Li X, Chan C, Yeo I . THREE-YEAR RESULTS OF POLYPOIDAL CHOROIDAL VASCULOPATHY TREATED WITH PHOTODYNAMIC THERAPY: Retrospective Study and Systematic Review. Retina. 2015; 35(8):1577-93. DOI: 10.1097/IAE.0000000000000499. View

10.

Doble B, Finkelstein E, Tian Y, Saxena N, Patil S, Wong T . Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy. JAMA Ophthalmol. 2020; 138(3):251-259. PMC: 6990685. DOI: 10.1001/jamaophthalmol.2019.5628. View

11.

Koh A, Lee W, Chen L, Chen S, Hashad Y, Kim H . EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012; 32(8):1453-64. DOI: 10.1097/IAE.0b013e31824f91e8. View

12.

Wong T, Ogura Y, Lee W, Iida T, Chen S, Mitchell P . Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study. Am J Ophthalmol. 2019; 204:80-89. DOI: 10.1016/j.ajo.2019.02.027. View

13.

Koh A, Chen L, Chen S, Chen Y, Giridhar A, Iida T . Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. 2013; 33(4):686-716. DOI: 10.1097/IAE.0b013e3182852446. View

14.

Lee W, Iida T, Ogura Y, Chen S, Wong T, Mitchell P . Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2018; 136(7):786-793. PMC: 6136040. DOI: 10.1001/jamaophthalmol.2018.1804. View

15.

Koh A, Lai T, Takahashi K, Wong T, Chen L, Ruamviboonsuk P . Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2017; 135(11):1206-1213. PMC: 5710379. DOI: 10.1001/jamaophthalmol.2017.4030. View

16.

Cho H, Baek J, Lee D, Kim C, Kim J . Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol. 2012; 26(3):157-62. PMC: 3364425. DOI: 10.3341/kjo.2012.26.3.157. View

17.

Bhoomibunchoo C, Yospaiboon Y, Thoongsuwan S, Rojanaporn D, Watanachai N, Jirarattanasopa P . Idiopathic polypoidal choroidal vasculopathy in Thai patients with clinical and angiographic choroidal neovascularization. Clin Ophthalmol. 2017; 11:317-322. PMC: 5308571. DOI: 10.2147/OPTH.S126226. View

18.

Chakravarthy U, Harding S, Rogers C, Downes S, Lotery A, Culliford L . Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 382(9900):1258-67. DOI: 10.1016/S0140-6736(13)61501-9. View

19.

Cheung C, Lai T, Ruamviboonsuk P, Chen S, Chen Y, Freund K . Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management. Ophthalmology. 2018; 125(5):708-724. DOI: 10.1016/j.ophtha.2017.11.019. View

20.

Dilokthornsakul P, Chaiyakunapruk N, Ruamviboonsuk P, Ratanasukon M, Ausayakhun S, Tungsomeroengwong A . Health resource utilization and the economic burden of patients with wet age-related macular degeneration in Thailand. Int J Ophthalmol. 2014; 7(1):145-51. PMC: 3949476. DOI: 10.3980/j.issn.2222-3959.2014.01.27. View